Effect of Lipid Abnormality on CKD Progression from Moderate to Severe Stage: Application of Flexible Parametric Proportional-Hazards and Proportional-Odds Models
暂无分享,去创建一个
[1] A. Žák,et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. , 2020, Vnitrni lekarstvi.
[2] H. Argani,et al. Protection of renal damage by HMG-CoA inhibitors: A comparative study between atorvastatin and rosuvastatin , 2020, Iranian journal of basic medical sciences.
[3] M. Hesaraki,et al. Prevalence of Chronic Kidney Disease in Iranian General Population: A Meta‐Analysis and Systematic Review , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[4] F. Kronenberg. HDL in CKD-The Devil Is in the Detail. , 2018, Journal of the American Society of Nephrology : JASN.
[5] B. Afşar,et al. Disorders of Lipid Metabolism in Chronic Kidney Disease , 2018, Blood Purification.
[6] Lala Septem Riza,et al. Detection of kidney disease using various intelligent classifiers , 2017, 2017 3rd International Conference on Science in Information Technology (ICSITech).
[7] N. A. Tutkun,et al. Flexible parametric survival models: An application to gastric cancer data , 2017 .
[8] Lisa R Tannock,et al. Dyslipidemia in patients with chronic kidney disease , 2017, Reviews in Endocrine and Metabolic Disorders.
[9] L. Orlić,et al. Dyslipidemia in patients with chronic kidney disease: etiology and management , 2017, International journal of nephrology and renovascular disease.
[10] D. Santoro,et al. Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease , 2016, Journal of clinical & translational endocrinology.
[11] M. Mansournia,et al. Flexible parametric survival models built on age-specific antimüllerian hormone percentiles are better predictors of menopause , 2016, Menopause.
[12] W. Kang,et al. Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women , 2016, Menopause.
[13] N. Baral,et al. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients , 2015, BMC Endocrine Disorders.
[14] Mostafa HOSSEINI,et al. A Comparison between Accelerated Failure-time and Cox Proportional Hazard Models in Analyzing the Survival of Gastric Cancer Patients , 2015, Iranian journal of public health.
[15] Lisa R Tannock. Dyslipidemia in Chronic Kidney Disease , 2015 .
[16] Akhilesh Rao,et al. Lipid abnormalities in kidney disease and management strategies. , 2015, World journal of nephrology.
[17] M. Kuo,et al. Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease , 2013, PloS one.
[18] M. Tonelli,et al. Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.
[19] Paul C. Lambert,et al. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .
[20] Paul C. Lambert,et al. Further Development of Flexible Parametric Models for Survival Analysis , 2009 .
[21] F. Azizi,et al. High prevalence of chronic kidney disease in Iran: a large population-based study , 2009, BMC public health.
[22] A. Khwaja,et al. The management of CKD: a look into the future. , 2007, Kidney international.
[23] N. Vaziri. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. , 2006, American journal of physiology. Renal physiology.
[24] A. Cases,et al. Dyslipidemia and the progression of renal disease in chronic renal failure patients. , 2005, Kidney international. Supplement.
[25] H. Bloomfield,et al. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] Daniel Levy,et al. Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.
[27] J. Buring,et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. , 2003, Journal of the American Society of Nephrology : JASN.
[28] R. Bigazzi,et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] P. Royston,et al. Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.
[30] J. Coresh,et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.
[31] M. Ravid,et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. , 1998, Archives of internal medicine.
[32] H. Wedel,et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] G. Beck,et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.
[34] V. Manninen,et al. Effects of hypertension and dyslipidemia on the decline in renal function. , 1995, Hypertension.
[35] A. Krolewski,et al. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. , 1994, Kidney international. Supplement.
[36] J. Mustonen,et al. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.